Claudia Bellofiore
Overview
Explore the profile of Claudia Bellofiore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Song A, Mellgard G, Bellofiore C, Basset M, Nuvolone M, Foli A, et al.
Blood Adv
. 2025 Feb;
PMID: 39977714
No abstract available.
2.
Milani P, Sanna G, Mussinelli R, Basset M, Guida G, Attanasio A, et al.
J Am Heart Assoc
. 2024 Dec;
14(1):e036755.
PMID: 39719432
Background: For the time being, tafamidis is the only approved treatment for wild-type transthyretin cardiac amyloidosis. However, benefits on all-cause death only emerge after ≈18 months. The current available staging...
3.
Milani P, Fabris F, Mussinelli R, Sanna G, Basset M, Benvenuti P, et al.
Amyloid
. 2024 Jul;
31(3):220-225.
PMID: 38989681
Background: Early identification of immunoglobulin light-chain amyloidosis (AL) is crucial due to its rapid progression. Monoclonal light-chain (M-LC) testing is the first step in the diagnostic workup for patients with...
4.
Bellofiore C, Palladini G, Milani P
Curr Oncol Rep
. 2024 Jun;
26(9):1097-1103.
PMID: 38896184
Purpose Of Review: This review aims to assess the therapeutic strategies available for relapsed/refractory patients with immunoglobulin light chain (AL) amyloidosis who received upfront daratumumab-based regimens. Recent Findings: The treatment...
5.
Bellofiore C, Benvenuti P, Mina R, Basset M, Foli A, Nanci M, et al.
Hematol Oncol
. 2024 Jun;
42(4):e3289.
PMID: 38824453
Daratumumab-based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real-world data on daratumumab efficacy in...
6.
Basset M, Schonland S, Obici L, Gunther J, Riva E, Dittrich T, et al.
J Am Soc Nephrol
. 2024 Mar;
35(6):782-794.
PMID: 38512269
No abstract available.
7.
Del Fabro V, Di Giorgio M, Leotta V, Duminuco A, Bellofiore C, Markovic U, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627065
Based on the results obtained in clinical trials, the use of the combination of lenalidomide and dexamethasone (Len/Dex) has become a potential therapeutic choice for newly diagnosed multiple myeloma (NDMM)...
8.
Basset M, Milani P, Foli A, Nuvolone M, Benvenuti P, Nanci M, et al.
Blood
. 2022 Jun;
140(18):1964-1971.
PMID: 35772003
Patients with immunoglobulin light chain (AL) amyloidosis and stage IIIb cardiac involvement have a dismal outcome despite the introduction of novel treatments. However, a rapid hematologic response translates in better...
9.
Bulla A, Markovic U, Bellofiore C, Stella S, Conticello C, Di Raimondo F, et al.
Cancer Diagn Progn
. 2022 Apr;
1(1):19-22.
PMID: 35399694
Background: The third-generation tyrosine kinase inhibitor ponatinib has demonstrated high clinical efficacy in the setting of patients with resistant chronic phase chronic myeloid leukemia (CML), also inducing deep molecular responses....
10.
Milone G, Bellofiore C, Leotta S, Milone G, Cupri A, Duminuco A, et al.
J Clin Med
. 2022 Feb;
11(3).
PMID: 35160072
Endothelial dysfunction (ED) is frequently encountered in transplant medicine. ED is an argument of high complexity, and its understanding requires a wide spectrum of knowledge based on many fields of...